+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Sarcoidosis Therapeutics Market 2019-2023 - Product Image

Global Sarcoidosis Therapeutics Market 2019-2023

  • ID: 4744677
  • Report
  • November 2018
  • Region: Global
  • 115 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Fresenius
  • Horizon Pharma
  • Mallinckrodt
  • Pfizer
  • MORE
Strategic alliances to gain traction in the market. Pharmaceutical companies are working together for the development of medications for the treatment of sarcoidosis. These alliances will enhance the R&D activities of new drugs for the management of sarcoidosis. The analysts have predicted that the sarcoidosis therapeutics market will register a CAGR of more than 4% by 2023.

Market Overview

Rising awareness about sarcoidosis

The signs and symptoms of sarcoidosis are very broad, sometimes resemble the symptoms of other diseases. The increase in the number of organizations and institutes that create awareness about sarcoidosis among people and is expected to propel growth of the global sarcoidosis therapeutics market during the forecast period.

Side effects of available medicines

Although several off-label medications are available for the symptomatic treatment of sarcoidosis, the side effects associated with them are decreasing their preference.

For the detailed list of factors that will drive and challenge the growth of the sarcoidosis therapeutics market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Fresenius and Horizon Pharma, the competitive environment is quite intense. Factors such as the rising awareness about sarcoidosis and the strategic alliances, will provide considerable growth opportunities to sarcoidosis therapeutics manufactures. Fresenius, Horizon Pharma, and Johnson & Johnson Services are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Fresenius
  • Horizon Pharma
  • Mallinckrodt
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Corticosteroids - Market size and forecast 2018-2023
  • Other therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Fresenius
  • Horizon Pharma
  • Johnson & Johnson Services
  • Mallinckrodt
  • Pfizer
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global rare diseases therapeutics market
Exhibit 03: Segments of global rare diseases therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Corticosteroids - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Corticosteroids - Year-over-year growth 2019-2023 (%)
Exhibit 22: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Other therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Market opportunity
Exhibit 38: Decision framework
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Fresenius - Vendor overview
Exhibit 46: Fresenius - Business segments
Exhibit 47: Fresenius - Organizational developments
Exhibit 48: Fresenius - Geographic focus
Exhibit 49: Fresenius - Segment focus
Exhibit 50: Fresenius - Key offerings
Exhibit 51: Fresenius - Key customers
Exhibit 52: Horizon Pharma - Vendor overview
Exhibit 53: Horizon Pharma - Business segments
Exhibit 54: Horizon Pharma - Organizational developments
Exhibit 55: Horizon Pharma - Geographic focus
Exhibit 56: Horizon Pharma - Key offerings
Exhibit 57: Horizon Pharma - Key customers
Exhibit 58: Johnson & Johnson Services - Vendor overview
Exhibit 59: Johnson & Johnson Services - Business segments
Exhibit 60: Johnson & Johnson Services - Organizational developments
Exhibit 61: Johnson & Johnson Services - Geographic focus
Exhibit 62: Johnson & Johnson Services - Segment focus
Exhibit 63: Johnson & Johnson Services - Key offerings
Exhibit 64: Johnson & Johnson Services - Key customers
Exhibit 65: Mallinckrodt - Vendor overview
Exhibit 66: Mallinckrodt - Business segments
Exhibit 67: Mallinckrodt - Organizational developments
Exhibit 68: Mallinckrodt - Geographic focus
Exhibit 69: Mallinckrodt - Segment focus
Exhibit 70: Mallinckrodt - Key offerings
Exhibit 71: Mallinckrodt - Key customers
Exhibit 72: Pfizer - Vendor overview
Exhibit 73: Pfizer - Business segments
Exhibit 74: Pfizer - Organizational developments
Exhibit 75: Pfizer - Geographic focus
Exhibit 76: Pfizer - Segment focus
Exhibit 77: Pfizer - Key offerings
Exhibit 78: Pfizer - Key customers
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: Information sources
Exhibit 81: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Fresenius
  • Horizon Pharma
  • Mallinckrodt
  • Pfizer
  • MORE
Global Sarcoidosis Therapeutics Market 2019-2023

The analyst recognizes the following companies as the key players in the global sarcoidosis therapeutics market: Fresenius, Horizon Pharma, and Johnson & Johnson Services.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the growing strategic alliances.”

According to the report, one of the major drivers for this market is the rising awareness about sarcoidosis.

Further, the report states that one of the major factors hindering the growth of this market is the side effects of available medicines.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Fresenius
  • Horizon Pharma
  • Johnson & Johnson Services
  • Mallinckrodt
  • Pfizer
Note: Product cover images may vary from those shown
Adroll
adroll